Shots:

• The P-III (ENHANCE-2) trial evaluates the efficacy & safety of ensifentrine (3mg) as monothx. & added on to LAMA or LABA vs PBO in 800 patients with COPD across US & EU for 24wks. The results are expected in Q3’22 while (ENHANCE-1) trial result at the end of 2022
• The 1EPs include an improvement in lung function over 12hrs. after 12wks. The 2EPs include COPD symptoms & health-related QoL @24wks. via validated PROs tools, SGRQ & E-RS while an additional lung function EPs including peak & morning trough FEV1 will also be evaluated
• The company is planning to file an NDA with the US FDA in H1’23. In prior clinical studies, the therapy showed improvements in lung function, symptoms & QoL

Ref: Globe Newswire | Image: Share Talk